Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Yoon Ho, Lee, Myung Ah, Hong, Yeong Seon, Lee, Kyung Shik, Park, Hyun Jin, Yoo, Ie Ryung, Kim, Yeon Sil, Kim, Young Kyoon, Jo, Keon Hyun, Wang, Young Pil, Lee, Kyo Young, Kang, Jin Hyoung
Formato: Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687691/
https://www.ncbi.nlm.nih.gov/pubmed/17939335
http://dx.doi.org/10.3904/kjim.2007.22.3.178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687691/
https://www.ncbi.nlm.nih.gov/pubmed/17939335
http://dx.doi.org/10.3904/kjim.2007.22.3.178

Ejemplares similares